Bayer (BAYRY)
(Delayed Data from OTC)
$7.19 USD
+0.01 (0.07%)
Updated Oct 18, 2024 03:59 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
Price, Consensus and EPS Surprise
BAYRY 7.19 +0.01(0.07%)
Will BAYRY be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BAYRY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BAYRY
Bayer Seeks Approval for Elinzanetant for Vasomotor Symptoms in EU
Roche Wins FDA Nod for Breast Cancer Drug in First-Line Setting
BAYRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
Regeneron Gains 13.5% Year to date: How to Play the Stock?
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
Other News for BAYRY
Bayer price target lowered by EUR 1 at Citi
Bayer Seeks European Approval For Its Menopause Drug
J.P. Morgan Sticks to Their Hold Rating for Bayer (0P6S)
Bayer Seeks European Approval For Third Indication For Cancer Drug Darolutamide
Goldman Sachs Reaffirms Their Hold Rating on Bayer (0P6S)